Skip to content
10-Q

Quarterly Report

RenovoRx, Inc. RNXT

0001193125-26-224100

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 45.1M sh
Shares Diluted Q1 2026 · Mar 31, 2026 38.03M sh
Shares Diluted Q1 2026 · Mar 31, 2025 31.4M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $2K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.71M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.38M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $12.36M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $7.02M
Stockholders Equity Q1 2026 · Mar 31, 2026 $11.27M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.42M
Stockholders Equity Q1 2026 · Mar 31, 2025 $13.16M
Stockholders Equity Q1 2026 · Dec 31, 2024 $4.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.92M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.96M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.7M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.67M
Current Assets Q1 2026 · Mar 31, 2026 $13.72M
Current Assets Q1 2026 · Dec 31, 2025 $7.89M
Total Assets Q1 2026 · Mar 31, 2026 $13.96M
Total Assets Q1 2026 · Dec 31, 2025 $8.1M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.09
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.08
Eps Basic Q1 2026 · Mar 31, 2026 −$0.09
Eps Basic Q1 2026 · Mar 31, 2025 −$0.08
Sga Expense Q1 2026 · Mar 31, 2026 $2.72M
Sga Expense Q1 2026 · Mar 31, 2025 $1.57M
Rd Expense Q1 2026 · Mar 31, 2026 $1.23M
Rd Expense Q1 2026 · Mar 31, 2025 $1.64M
Net Income Q1 2026 · Mar 31, 2026 −$3.52M
Net Income Q1 2026 · Mar 31, 2025 −$2.42M
Operating Income Q1 2026 · Mar 31, 2026 −$3.47M
Operating Income Q1 2026 · Mar 31, 2025 −$3.11M
Gross Profit Q1 2026 · Mar 31, 2026 $479K
Gross Profit Q1 2026 · Mar 31, 2025 $103K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $84K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $94K
Revenue Q1 2026 · Mar 31, 2026 $563K
Revenue Q1 2026 · Mar 31, 2025 $197K